MX2018003096A - Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma. - Google Patents

Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.

Info

Publication number
MX2018003096A
MX2018003096A MX2018003096A MX2018003096A MX2018003096A MX 2018003096 A MX2018003096 A MX 2018003096A MX 2018003096 A MX2018003096 A MX 2018003096A MX 2018003096 A MX2018003096 A MX 2018003096A MX 2018003096 A MX2018003096 A MX 2018003096A
Authority
MX
Mexico
Prior art keywords
anionic drug
pharmaceutical composition
preparation
method therefor
composition containing
Prior art date
Application number
MX2018003096A
Other languages
English (en)
Inventor
Hoon Kim Sang
Hyo SEO Min-
Yeong Nam Hye
Oh Kim Bon-
Yeon Son Ji-
Hye CHOI Ji-
Original Assignee
Samyang Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samyang Biopharmaceuticals filed Critical Samyang Biopharmaceuticals
Priority claimed from PCT/KR2016/010269 external-priority patent/WO2017048018A1/ko
Publication of MX2018003096A publication Critical patent/MX2018003096A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Abstract

Se describen una composición farmacéutica para suministro de fármaco aniónico, y un método de preparación para la misma, la composición farmacéutica para suministro de fármaco aniónico que contiene: un fármaco aniónico como un ingrediente activo; un compuesto catiónico; un copolímero de bloque anfifílico; y un polilactato, en donde el fármaco aniónico formó un complejo con el lípido catiónico, y el complejo se encapsula dentro de una estructura micelar formada por el copolímero de bloque anfifílico y el polilactato.
MX2018003096A 2015-09-15 2016-09-12 Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma. MX2018003096A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150130587 2015-09-15
KR1020160117053A KR101828877B1 (ko) 2015-09-15 2016-09-12 음이온성 약물 함유 약제학적 조성물 및 그 제조방법
PCT/KR2016/010269 WO2017048018A1 (ko) 2015-09-15 2016-09-12 음이온성 약물 함유 약제학적 조성물 및 그 제조방법

Publications (1)

Publication Number Publication Date
MX2018003096A true MX2018003096A (es) 2018-05-11

Family

ID=58496160

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003096A MX2018003096A (es) 2015-09-15 2016-09-12 Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.

Country Status (16)

Country Link
US (2) US11253598B2 (es)
EP (1) EP3357491B1 (es)
JP (1) JP6638072B2 (es)
KR (2) KR101828877B1 (es)
CN (1) CN108024960B (es)
AU (1) AU2016324450B2 (es)
CA (1) CA2998092C (es)
DK (1) DK3357491T3 (es)
ES (1) ES2883290T3 (es)
HK (1) HK1251464A1 (es)
IL (1) IL257937B (es)
MX (1) MX2018003096A (es)
PT (1) PT3357491T (es)
RU (1) RU2721558C2 (es)
SG (1) SG11201802073YA (es)
ZA (1) ZA201802303B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3391875T (pt) * 2015-12-18 2021-12-20 Samyang Holdings Corp Método para preparar micelas poliméricas contendo fármaco aniónico
KR102175069B1 (ko) * 2017-11-10 2020-11-05 주식회사 삼양바이오팜 음이온성 약물 전달용 지질 나노입자의 동결건조 조성물 및 방법
KR102259513B1 (ko) * 2017-11-16 2021-06-02 주식회사 삼양홀딩스 음이온성 약물 함유 약제학적 조성물의 동결건조 조성물 및 방법
KR20190127277A (ko) * 2018-05-04 2019-11-13 주식회사 삼양바이오팜 mRNA 전달용 고분자 나노입자 조성물 및 그 제조방법
CN109136271B (zh) * 2018-09-20 2021-07-20 西北工业大学 阳离子聚乙烯胺线形高分子作为转基因载体的应用
US20220409710A1 (en) 2019-11-07 2022-12-29 Samyang Holdings Corporation Polymer nanoparticle composition for inducing immunity and preparation method therefor
CN114980870A (zh) * 2019-11-22 2022-08-30 三养控股公司 用于制备药物递送用纳米颗粒组合物的试剂盒
EP4079298A4 (en) * 2019-12-20 2024-01-17 Samyang Holdings Corp KIT FOR PRODUCING A NANOPARTICLE COMPOSITION FOR ACTIVE DELIVERY WITH POLYLACTIC ACID SALT
JP2024515387A (ja) * 2021-04-30 2024-04-09 サムヤン ホールディングス コーポレイション 両親媒性高分子を含まないナノ粒子を含む薬物送達用組成物
GB202108444D0 (en) * 2021-06-14 2021-07-28 Imperial College Innovations Ltd Sub-micron particle
CN114569577B (zh) * 2022-03-07 2023-04-11 晟迪生物医药(苏州)有限公司 一种聚合物包衣纳米粒及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US6458382B1 (en) 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
NZ553687A (en) 2000-03-30 2010-03-26 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
EP1463518A2 (en) 2001-12-28 2004-10-06 Supratek Pharma, Inc. Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression
AU2003288902A1 (en) * 2002-09-06 2004-04-08 Genteric, Inc. Microcapsules and methods of use
KR100829799B1 (ko) * 2004-05-06 2008-05-16 주식회사 삼양사 양친성 블록 공중합체 및 폴리락트산 유도체를 포함하는 고분자 약물 담체에 기초한 생물 활성제의 세포내 전달용 조성물
KR100949791B1 (ko) 2007-12-18 2010-03-30 이동기 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
US20090312402A1 (en) * 2008-05-20 2009-12-17 Contag Christopher H Encapsulated nanoparticles for drug delivery
US20100028416A1 (en) * 2008-07-30 2010-02-04 Nitto Denko Corporation Drug carriers
MX2011006537A (es) 2008-12-26 2011-07-20 Samyang Corp Metodo de preparacion de una composicion de nanoparticulas micelares polimericas que contienen un farmaco probremente soluble en agua.
JP5592897B2 (ja) 2008-12-26 2014-09-17 サムヤン バイオファーマシューティカルズ コーポレイション アニオン性薬物含有薬剤学的組成物及びその製造方法
KR101296326B1 (ko) 2009-12-30 2013-08-14 주식회사 삼양바이오팜 폴리락트산을 포함하는 음이온성 약물 전달용 조성물 및 그 제조 방법
JP5826174B2 (ja) * 2010-07-09 2015-12-02 国立大学法人 東京大学 核酸送達用組成物及び担体組成物、それを用いた医薬組成物、並びに核酸送達方法
AU2011353233B2 (en) * 2010-12-30 2016-02-11 Samyang Holdings Corporation Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
EP2833869B1 (en) * 2012-04-04 2020-10-28 Samyang Biopharmaceuticals Corporation Method of preparing composition for delivering an anionic drug
KR102109188B1 (ko) 2013-04-01 2020-05-11 삼성전자주식회사 양이온성 지질을 포함하는 온도민감성 리포좀 및 그의 용도
US20170000740A9 (en) 2013-04-09 2017-01-05 University Of Georgia Research Foundation Inc. Combination therapeutic nanoparticles

Also Published As

Publication number Publication date
KR101948839B1 (ko) 2019-02-15
KR101828877B1 (ko) 2018-02-14
PT3357491T (pt) 2021-08-02
DK3357491T3 (da) 2021-08-02
IL257937B (en) 2020-10-29
HK1251464A1 (zh) 2019-02-01
KR20180008854A (ko) 2018-01-24
US20220125929A1 (en) 2022-04-28
RU2721558C2 (ru) 2020-05-20
ES2883290T3 (es) 2021-12-07
CN108024960A (zh) 2018-05-11
EP3357491B1 (en) 2021-06-02
CN108024960B (zh) 2020-12-29
EP3357491A4 (en) 2019-05-08
RU2018113459A (ru) 2019-10-18
US11253598B2 (en) 2022-02-22
SG11201802073YA (en) 2018-04-27
JP6638072B2 (ja) 2020-01-29
EP3357491A1 (en) 2018-08-08
AU2016324450B2 (en) 2019-04-18
KR20170032858A (ko) 2017-03-23
ZA201802303B (en) 2019-01-30
CA2998092C (en) 2020-08-04
RU2018113459A3 (es) 2019-10-18
IL257937A (en) 2018-05-31
AU2016324450A1 (en) 2018-04-12
CA2998092A1 (en) 2017-03-23
US20180250409A1 (en) 2018-09-06
JP2018527413A (ja) 2018-09-20

Similar Documents

Publication Publication Date Title
MX2018003096A (es) Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.
MY190561A (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2018002627A (es) Metodo de cristalizacion y biodisponibilidad.
MX359288B (es) Forma iv del clorhidrato de ivabradina.
MX2017010102A (es) Conjugado farmaco citotoxico-ligando, metodo de preparacion del mismo, y sus aplicaciones.
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
NZ743320A (en) Method for preparing polymeric micelle containing anionic drug
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
MX2016001422A (es) Composicion farmaceutica de fingolimod.
EP3168214A4 (en) Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical composition, medicinal preparation, method for treating prostate cancer
BR112016014880A2 (pt) Composição farmacêutica incluindo palonosetron
EP3138834A4 (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX363530B (es) Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo.
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
MX2015005762A (es) Producto de comicronizacion que comprende acetato de ulipristal.
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
WO2015001163A3 (es) Nanopartículas lipídicas para la cicatrización de heridas
EP3615011A4 (en) PHARMACEUTICAL COMPOSITION FOR IN VIVO ADMINISTRATION, PROCESS FOR THE PREPARATION OF A PHARMACOLOGICALLY ACTIVE PRINCIPLE SENSITIVELY INSOLUBLE IN WATER
AU2015303724B2 (en) Quinazoline derivative
MY183068A (en) Pharmaceutical formulation comprising antibody
EP2875814A4 (en) LIQUID COMPOSITION CONTAINING TAXANE ACTIVE INGREDIENT, MANUFACTURING METHOD THEREOF, AND LIQUID MEDICINAL PREPARATION
PH12016501117A1 (en) Pharmaceutical compositions of carotenoid
EA201691741A1 (ru) Фармацевтическая композиция
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.